Home›Trial›NCT06129240
NCT06129240ACTIVE NOT RECRUITING

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Study Summary

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

Conditions
Pulmonary HypertensionInterstitial Lung Disease
Interventions / Drugs
LIQ861
View on ClinicalTrials.gov ↗
Sponsor
LQDA
Liquidia Technologies
Pulmonary
D35/100
Study Details
Enrollment80 participants
Primary Completion—
Lead SponsorLiquidia Technologies, Inc.
Data Retrieved2026-04-11 04:20:00.960761+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 80 participants
Sponsor Catalyst Profile

Liquidia Technologies (LQDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

LQDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.